XERIS BIOPHARMA HOLDINGS, INC. Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions of $1.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions · last filed 2026-03-02
- XERIS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2025 was $1.00K, a 97.67% decline from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2024 was $43.00K, a 53.57% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2023 was $28.00K, a 833.33% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. unrecognized tax benefits, decrease resulting from prior period tax positions for fiscal 2022 was $3.00K, a 99.06% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions 12 month |
|---|---|
| 2025-12-31 | $1.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $43.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | $28.00K 10-K · filed 2026-03-02 |
| 2022-12-31 | $3.00K 10-K · filed 2025-03-06 |
| 2021-12-31 | $319.00K 10-K · filed 2024-03-06 |
| 2020-12-31 | $64.00K 10-K · filed 2022-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |